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multiplied with 2004 UK unit cost. A total of 1505 COPD
patients with post FEV1% pred < = 50% were included (roﬂu-
milast 755, placebo 750). 62% were taking inhaled corticos-
teroids. RESULTS: In the total group, COPD-related costs from
a societal perspective were €1635 (roﬂumilast) and €1400
(placebo). From a payer’s perspective this was €1385 and €1253,
respectively. The overall rate of mod/sev COPD exacerbations in
the trial was low and no differences existed between roﬂumilast
(0.96) and placebo (1.06). In a subgroup of patients with very
severe COPD (n = 223), placebo was associated with a high exac-
erbation rate (1.7 exacerbations/patient/year) and roﬂumilast
was associated with 35% fewer exacerbations. This lower exac-
erbation rate was associated with €1001 lower COPD-related
treatment costs. In the subgroup of patients with high health care
resource use prior to the study (n = 549) the roﬂumilast group
showed 0.41 fewer exacerbations per patient per year, which
translated into an ICER of €804 per mod/sev exacerbation
avoided. CONCLUSION: These data suggest that roﬂumilast,
like many newly introduced therapies, increases the overall cost
of therapy for COPD; however, this increase was partly offset by
savings. Furthermore, in this study, roﬂumilast was found to be
cost saving in very severe patients.
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OBJECTIVE: The incidence of community-acquired pneumonia
(CAP) caused by drug resistance has increased dramatically in
recent years. The aim of this analysis was to analyse the impact
of antimicrobial resistance on the cost-effectiveness of different
antibiotic classes (beta-lactams, macrolides, ﬂuoroquinolones) in
patients with CAP in Germany. METHODS: A decision analytic
model was developed for mild-to-moderate CAP outpatient
treatment. Treatment algorithms incorporated follow-up after
treatment failure due to resistance or other reasons. First-line
treatment included moxiﬂoxacin (MXF), beta-lactams (AMX),
or macrolides (ROX); second-line treatment used a different
antimicrobial class. In contrast to existing cost-effectiveness
models in CAP class-speciﬁc resistance proﬁles were included in
the model. This allows for the analysis of the impact of antimi-
crobial resistance on the cost-effectiveness in addition to stan-
dard outcomes like clinical failure, hospitalisation rates and total
costs. Input data were derived from surveillance studies, from lit-
erature and expert opinion. Total costs were estimated using
standard sources and a third-party payer perspective in Germany.
RESULTS: Total cost were €240.60 (MXF), €250.59 (ROX), and
€268.91 (AMX). First-line clinical failure, second-line treatment,
and hospitalisation rates were lower for MXF as compared to
the other treatment options. First-line MXF treatment domi-
nated all other treatments. Antimicrobial resistance accounted
for 53% (AMX), 72% (ROX) and 2% (MXF) of all clinical fail-
ures and 37% (AMX), 56%(ROX) and 1% (MXF) of all hos-
pitalisations. CONCLUSIONS: Antimicrobial resistance has a
signiﬁcant impact on the cost-effectiveness of empirical treat-
ment of CAP. The ﬁrst-line use of moxiﬂoxacin in CAP is a dom-
inant strategy even in a country with a low level of resistance
like Germany.
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OBJECTIVES: Exacerbations are the key drivers of the costs of
chronic obstructive pulmonary disease (COPD). This was the
pilot study of patients with COPD aimed at evaluating direct and
indirect cost of exacerbations under usual clinical practice in
primary and secondary care form societal perspective.
METHOD: It was observational, multicenter study with partic-
ipation of 73 subjects with moderate or severe COPD, deﬁned
according to the current GOLD criteria. Patients presenting at
the selected health care centres were included into the study in
the sequential manner, if they fulﬁlled the inclusion criteria.
Exacerbations were divided into three different severity types
according to Anthonisen N.R. classiﬁcation. The management of
exacerbations followed the usual clinical practice. RESULTS:
The average monthly cost of maintenance therapy of COPD was
ca. PLN 180. The average direct health care cost per exacerba-
tion was PLN 4002 (95% CI = 3537; 4503) and PLN 438 (95%
CI = 326; 570) in secondary and primary care respectively. In
secondary care, the drug acquisition and oxygen therapy cost
represented 18.3% of total direct costs, diagnostic tests costs
accounted for 14.5%, the other hospital care and post-discharge
follow-up visit costs 67%. Costs varied considerably with the
severity of the exacerbation as well as the duration of COPD. In
primary care the cost structure was as follows: diagnostic tests
and medical devices 47.5%, drug acquisition costs 41% and
doctors visits 11.4%. The average indirect costs per exacerba-
tion were PLN 232 and PLN 141, in secondary and primary
respectively. (EUR 1 = PLN 3,85; year 2006). The average
reported number of COPD exacerbations in previous year was
3. CONCLUSION: Exacerbations of COPD are costly. Cost of
exacerbation managed in secondary care is 9-fold higher than in
primary care. Prevention of moderate-to-severe exacerbations,
requiring hospitalization could be very cost-effective strategy.
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OBJECTIVES: In 2004, diagnosis-related groups (DRGs) had
been implemented for the reimbursement of hospitals instead of
daily lump sum. We analysed the effect of DRG-implementation
on direct costs of hospitals on the basis of in-patient treatment
of community-acquired pneumonia (CAP). METHODS: This
open, prospective observational study was divided into two
parts. First part was performed between October 2002 and July
2003, the second in 2005. In-patients suffering from CAP were
enrolled. The perspective of hospital management was applied
for calculation of costs for drug acquisition, non-medical
therapy, diagnostic procedures, hotel and staff. The quantity
aspect of treatment was documented by the physicians. Infor-
mation on the costs per measure was provided by the hospital
controller. RESULTS: In 2002/2003, 319 patients (cohort A)
were documented in 9 hospitals. In 2005, 322 patients (cohort
